Clik here to view.
UPDATE: Covidien closes ev3 buyout
Covidien plc (NYSE:COV) consummated a $2.6 billion deal to acquire ev3 Inc. (NSDQ:EVVV), hours after closing its tender offer for shares in the Minnesota vascular device maker. Mansfield, Mass.-based...
View ArticleClik here to view.
Developing cancer treatment from a patient’s cancerous cells
By Carol Cruzan Morton In a roomful of kids’ cancer specialists, like those listening to the keynote speech by Dr. George Daley, closing an international pediatric oncology meeting in Boston, the Myc...
View ArticleClik here to view.
Ev3 recalls peripheral artery dilation catheter
Ev3 Inc. initiated a recall for certain lots of its NanoCross .014″ OTW PTA dilatation catheter. The Plymouth, Minn.-based Covidien plc (NYSE:COV) subsidiary is taking the peripheral artery surgical...
View ArticleClik here to view.
Covidien’s Pipeline aneurysm device wins FDA panel nod
An FDA panel gave the nod to Covidien plc’s (NYSE:COV) Pipeline embolization device, recommending that it be approved to treat large brain aneurysms. Covidien acquired the technology with its $2.6...
View ArticleClik here to view.
Covidien closes enrollment on ev3 atherectomy device study
Covidien plc (NYSE:COV) said it has enough patients to evaluate the effectiveness of an arterial plaque removal system it acquired in its buyout of ev3 Inc. last year. The Mansfield, Mass.-based...
View ArticleClik here to view.
Covidien completes enrollment on ev3 atherectomy device study | Research roundup
Covidien plc (NYSE:COV) said it has enough patients to evaluate the effectiveness of an arterial plaque removal system it acquired in its buyout of ev3 Inc. last year. The Mansfield, Mass.-based...
View ArticleClik here to view.
ev3 pays off big for Covidien
The flurry of moves Covidien plc (NYSE:COV) made in 2010 are starting to pay off for the Mansfield, Mass.-based medical products conglomerate. New business from its $2.6 billion ev3 acquisition helped...
View ArticleClik here to view.
Med-tech in the OC: A Q&A with OCTANe’s Matthew Jenusaitis
Matthew Jenusaitis knows a little something about regional hotbeds of innovation in the med-tech space. Having spent 15 years at Boston Scientific Corp. (NYSE:BSX) in numerous executive marketing and...
View ArticleClik here to view.
Covidien names new vascular leader | Personnel Moves
Covidien (NYSE:COV) named Stacy Enxing Seng president of its $1.4 billion global vascular therapies business. Enxing Seng, 47, will lead the division’s 4,000 employees, reporting to Peter Wehrly,...
View ArticleClik here to view.
Covidien touts FDA clearance for “game-changing” Solitaire revascularization...
Covidien plc (NYSE:COV) won FDA clearance for its Solitaire FR revascularization device for removing blood clots and restoring blood flow in the brains of patients suffering acute ischemic stroke. The...
View ArticleClik here to view.
FDA warns on Covidien’s liquid embolic system following 9 patient deaths
The FDA issued a safety alert after receiving reports of more than 100 adverse events, including 9 patient deaths, that may have been caused by Onyx brain blood vessel plugs made by Covidien...
View ArticleClik here to view.
Layoffs: Covidien to shutter South Carolina plant, cutting 595 jobs
Covidien (NYSE:COV) will close a manufacturing facility in Seneca, S.C., and move the operation to Costa Rica, resulting in nearly 600 layoffs. The Seneca facility manufactures vascular products for...
View ArticleClik here to view.
Mixed feelings for Covidien’s Pipeline embolization device following deaths
Researchers offered mixed messages on the safety and effectiveness of Covidien (NYSE:COV) subsidiary ev3 Inc.’s Pipeline embolization device, lauding the system as an option for patients with...
View ArticleClik here to view.
Aneurysm: Covidien touts pivotal study on Pipeline embolization device
Covidien (NYSE:COV) subsidiary ev3 Inc. is touting the results of a pivotal trial of its Pipeline aneurysm embolization device, showing that the technology "offers a reasonably safe and effective...
View ArticleClik here to view.
Jury hands Covidien’s ev3 subsidiary a possible $275M loss
Covidien (NYSE:COV) is on the hook for a $175 million milestone owed by subsidiary ev3 Inc. to a company it acquired 11 years ago, plus another possible $100 million in interest, after a Delaware...
View ArticleClik here to view.
Covidien’s got a ‘new approach’ to peripheral arterial disease
Massachusetts medical device giant Covidien (NYSE:COV) released results from a pair of studies, supporting use of the company’s EverFlex self-expanding stent and combining directional atherectomy with...
View ArticleClik here to view.
Covidien’s ev3 seeks new trial in $175M loss to Appriva
Covidien (NYSE:COV) subsidiary ev3 wants the Delaware Supreme Court to grant a new trial in a lawsuit over $175 million ev3 allegedly owes its own Appriva Medical acquisition. Last summer a jury in...
View ArticleClik here to view.
Medtech legal news for the week of Mar. 17, 2014
Appeals court applies Supreme Court ruling to Medtronic lawsuit against Boston Scientific March 12, 2014 by Brad Perriello A federal appeals court today reconsidered a lawsuit between Medtronic and...
View ArticleClik here to view.
Covidien’s Ev3 logs a pair of legal wins over Appriva, whistleblower
Covidien (NYSE:COV) subsidiary Ev3 logged a pair of legal wins in recent weeks when the Delaware Supreme Court overturned a $250 million loss to Ev3 acquisition Appriva Medical and a federal judge in...
View ArticleClik here to view.
Medtronic shareholder sues over company’s plan to cover nearly $58M in taxes...
Shareholder sues Medtronic over plan to cover execs' $58m tax tab October 7, 2014 by Brad Perriello A Medtronic shareholder sued the company last week over its plan to cover nearly $58 million in...
View Article